AUPH · Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Market Cap
2.064B
52 Wk Range
$13.52 - $19.25
Previous Close
$15.40
Open
$15.30
Volume
170,891
Day Range
$15.11 - $15.45
Enterprise Value
1.635B
Cash
486.9M
Avg Qtr Burn
N/A
Insider Ownership
6.74%
Institutional Own.
60.12%
Qtr Updated
Sep 30th 2026
